R. B. Moss, MD, F. Carleton, PhD, C. P. Lollo, PhD, and D. J. Carlo, PhD, “An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 mL of intramuscular naloxone hydrochloride to 2 mg/0.4 mL intramuscular naloxone hydrochloride autoinjector in healthy subjects”, J of Opioid Management, vol. 16, no. 3, pp. 209–214, May 2020.